Live Chat

Los Contratos por diferencia («CFD») son instrumentos complejos que comportan un riesgo elevado de pérdidas rápidas debido al apalancamiento. El 76,3% de las cuentas de inversores particulares pierde dinero al operar CFD con este proveedor. Debe considerar si comprende el funcionamiento de los CFD y si puede permitirse asumir un riesgo elevado de perder su dinero.

Close

Opere Vir Biotechnology VIR

VirBiotechnology gráfico en tiempo real

Perspectivas

Weekly Search
Weekly
Daily
date Cerrar change Cambio del % Apertura Alto Bajo

Markets.com news

bitcoin rising
Alec Malloy 2024 Aug 19, 16:05

Test News Spanish Article Only

BoE Acciones
French election results to drive European markets
markets.com Support Team 2024 Jul 04, 21:00

Adelanto semanal: Los resultados de las elecciones francesas clave para los mercados europeos

Forex Índices
Macron calls snap election, riles markets
markets.com Support Team 2024 Jun 29, 21:00

Adelanto semanal: ¿Francia desencadenará la próxima crisis del euro?

CPI
Businessman pointing hologram online banking icon.
markets.com Support Team 2024 Jun 20, 16:00

Adelanto semanal: Muchos datos e información sobre la inflación

Forex Índices

Información

Spread

0.05

Spread (%)

0.6623 %

Apalancamiento

1:5

Interés a un día (Compra)

-0.0597 %

Interés a un día (Venta)

-0.0292 %

Divisa

USD

Horarios de los mercados

Markets closed

Martes

14:31 - 20:59

Lunes

14:31-20:59

Miércoles

14:31-20:59

Jueves

14:31-20:59

Viernes

14:31-20:59

Estado de resultados

Apertura

---

Cierre anterior

---

Máximo/mínimo de 52 semanas

--- – ---

Capitalización de mercado

1010864832

Acciones en circulación

137720000

Fecha de ganancias (próxima)

0000-00-00

instr__dividend_date

instr__ex_dividend_date

instr__forward_annual_dividend_rate

0

instr__forward_annual_dividend_yield

0

GPA

-3.93

Acciones en circulación

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Conoce más sobre este instrumento

Activo
Vender
Comprar
Cambio del %
Instrumentos relacionados
Trustpilot
Live Chat